Dolutegravir

Published November 04, 2012
Susa Coffey, MD
http://hivinsite.ucsf.edu/InSite?page=ar-07-03
Selected Reference
2. Walmsley S, Antela A, Clumeck N, et al. Dolutegravir (DTG; S/GSK1349572) + abacavir/lamivudine once daily statistically superior to tenofovir/emtricitabine/efavirenz: 48-week results--SINGLE (ING114467). In: Program and abstracts of the 52nd International Conference on Antimicrobials and Chemotherapy; September 9-12, 2012; San Francisco. Presentation H-556b.